Crossmark

Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells

Crossref DOI link: https://doi.org/10.1186/s13046-022-02360-y

Published Online: 2022-04-13

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pescatori, Sara

Leone, Stefano

Cipolletti, Manuela

Bartoloni, Stefania

di Masi, Alessandra

Acconcia, Filippo https://orcid.org/0000-0002-4651-2509
Funding

Funding for this research was provided by:

Associazione Italiana per la Ricerca sul Cancro (IG2018-ID21325)

Ministero dell’Istruzione, dell’Università e della Ricerca (The Grant of Excellence Departments (ARTICOLO 1, COMMI 314 – 337 LEGGE 232/2016))
License Information

Text and Data Mining valid from 2022-04-13

Version of Record valid from 2022-04-13
More Information

Article History

Received: 5 February 2022

Accepted: 7 April 2022

First Online: 13 April 2022

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below